In Vitro Activity of Tedizolid in Comparison with Other Oral and Intravenous Agents Against a Collection of Community-Acquired Methicillin-Resistant Staphylococcus aureus (2014-2015) in the United States

Microb Drug Resist. 2019 Jul/Aug;25(6):938-943. doi: 10.1089/mdr.2018.0410. Epub 2019 Jan 29.

Abstract

Tedizolid activity was compared with other agents with oral and intravenous formulations against community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA). Tedizolid (MIC50/90, 0.12/0.12 mg/L; 100.0% susceptible) was the most potent agent tested against CA-MRSA and subsets from adult and pediatric patients. Tedizolid minimum inhibitory concentrations (MICs) were twofold to fourfold lower than daptomycin (MIC50/90, 0.25/0.5 mg/L; 99.9-100% susceptible) and fourfold to eightfold lower than linezolid (MIC50/90, 1/1 mg/L; 100.0% susceptible), ceftaroline (MIC50/90, 0.5-1/1 mg/L; 96.6-98.8% susceptible), and vancomycin (MIC50/90, 0.5-1/1 mg/L; 100.0% susceptible) against CA-MRSA and subsets. Clindamycin resistance rates among CA-MRSA from pediatric and adult patients were 18.3-19.1% (13.4-14.2% constitutive, 4.9-6.4% inducible) and 36.2-37.6% (29.8-30.1% constitutive, 6.4-7.5% inducible), respectively. Tetracycline (90.4-96.4% susceptible) and trimethoprim-sulfamethoxazole (96.2-100.0% susceptible) were active against CA-MRSA or subsets, whereas erythromycin (83.8-89.4% nonsusceptible) and levofloxacin (50.2-70.8% nonsusceptible) had limited activities. Tedizolid had MIC50/90 values of 0.12/0.12 mg/L against CA-MRSA showing clindamycin constitutive-resistance and recovered from adult or pediatric patients. Tedizolid had potent activities against CA-MRSA, regardless of clindamycin phenotype or patient population. Tedizolid may be considered for the treatment of ABSSSI in adults. Further studies are warranted for the clinical development in the pediatric population.

Keywords: CA-MRSA; Sivextro; clindamycin; oxazolidinone.

MeSH terms

  • Adolescent
  • Anti-Bacterial Agents / therapeutic use*
  • Community-Acquired Infections / drug therapy*
  • Community-Acquired Infections / microbiology
  • Female
  • Humans
  • Male
  • Methicillin / therapeutic use*
  • Methicillin-Resistant Staphylococcus aureus / drug effects*
  • Microbial Sensitivity Tests / methods
  • Oxazolidinones / therapeutic use*
  • Staphylococcal Infections / drug therapy*
  • Staphylococcal Infections / microbiology
  • Tetrazoles / therapeutic use*
  • United States

Substances

  • Anti-Bacterial Agents
  • Oxazolidinones
  • Tetrazoles
  • tedizolid
  • Methicillin